Recently launched trial investigates anecortave acetate for preventing AMD progression to exudative disease

Enrollment has recently begun in the anecortave acetate risk reduction(AART) study that is designed to evaluate the efficacy of that angiostaticsteroid for reducing the risk of progression from dry to exudative age-relatedmacular degeneration (AMD), said Jason S. Slakter, MD.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.